{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_2",
        "name": "Tetrathiomolybdate Washout Period",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Experimental Therapy Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_4",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_5",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_6",
        "name": "Run-in Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_7",
        "name": "Baseline Balance Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "Initial 15mg/day Treatment Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "Initial 15mg/day I/O Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_10",
        "name": "CRU Re-admission Window",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_11",
        "name": "15mg/day Steady State I/O Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_12",
        "name": "30mg/day Treatment Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_13",
        "name": "30mg/day I/O Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_14",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_15",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "ALT Elevation for Dose Interruption",
        "instanceType": "Condition",
        "description": "Alanine aminotransferase level that triggers a temporary interruption of dosing.",
        "text": "ALT > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_2",
        "name": "ALT Elevation for Discontinuation",
        "instanceType": "Condition",
        "description": "Alanine aminotransferase level that triggers permanent discontinuation of dosing.",
        "text": "ALT > 5 × ULN"
      },
      {
        "id": "cond_3",
        "name": "Neutropenia for Dose Reduction",
        "instanceType": "Condition",
        "description": "Decrease in neutrophil count that triggers a dose reduction.",
        "text": "> 30% ↓ from baseline Neutrophils below reference range at baseline"
      },
      {
        "id": "cond_4",
        "name": "Potential Liver Injury for Dose Interruption",
        "instanceType": "Condition",
        "description": "Combination of elevated bilirubin and ALT that triggers a temporary dose interruption.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury"
      },
      {
        "id": "cond_5",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening that requires evaluation for dose modification.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_6",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of psychiatric worsening that requires evaluation for dose modification.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_7",
        "name": "Safety Review for Dose Titration",
        "instanceType": "Condition",
        "description": "Safety Review Committee must review data before dose titration.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_8",
        "name": "Adaptive Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "The outpatient period can be extended with Investigator approval.",
        "text": "To ensure flexibility, the Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Enrollment",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "Screening",
        "toElementId": "Run-in",
        "text": "participants who sign the informed consent form (ICF), are eligible for the study, and are registered on Day -7 when participants are assigned a participant number."
      },
      {
        "id": "trans_2",
        "name": "Dose Titration to 30mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_3",
        "name": "Dose Interruption for ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT > 3 × ULN and ≤ 5 × ULN, temporary interruption of dosing is required."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or to 15 mg QOD."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Potential Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2 × ULN accompanied by ALT > 3 × ULN, temporary interruption of dosing is required."
      },
      {
        "id": "trans_6",
        "name": "Discontinuation for Severe ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT > 5 × ULN, discontinue study intervention."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Hypersensitivity",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if... Serious hypersensitivity reaction."
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for Infection",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if... Severe uncontrolled infection."
      },
      {
        "id": "trans_9",
        "name": "Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if... Use of disallowed medication."
      },
      {
        "id": "trans_10",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if... Pregnancy or planned pregnancy."
      },
      {
        "id": "trans_11",
        "name": "Optional Dose Maintenance at 15mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "participants may remain on the 15 mg/day dose for the duration of the study... if there are safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk"
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretion Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor or Investigator Termination of Study Site",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason... The Investigator may initiate study-site closure at any time, provided there is reasonable cause and sufficient notice is given."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 23-29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point prior to Day 29 to determine if a participant can be titrated from 15 mg/day to 30 mg/day based on SRC review of safety data through Day 23.",
        "conditionIds": [
          "cond_7"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Safety-Based Dose Modification",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing monitoring of safety parameters (liver function, blood counts, neurologic/psychiatric status) that may trigger a dose modification, interruption, or discontinuation.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6"
        ]
      },
      {
        "id": "dec_3",
        "name": "Outpatient Period Extension Decision",
        "timepointId": "Day 9",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At the end of the first inpatient period, the Investigator may decide to extend the subsequent outpatient period by up to 14 days.",
        "conditionIds": [
          "cond_8"
        ]
      }
    ],
    "summary": {
      "timingCount": 15,
      "conditionCount": 8,
      "transitionRuleCount": 11,
      "exitCount": 5
    }
  }
}